Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros











Intervalo de año de publicación
1.
BMC Palliat Care ; 23(1): 16, 2024 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-38212798

RESUMEN

BACKGROUND: Despite being driven by a strong sense of duty and familial obligation, providing care for patients nearing the end of life poses challenges for family caregivers. Telemedicine has rapidly gained traction as a transformative approach to healthcare delivery, offering an array of benefits that could be particularly valuable in end-of-life care. However, research on the perspectives of telemedicine-based services among family caregivers of patients with end-of-life cancer is limited. Therefore, this study aims to explore the perspectives and preferences of telemedicine-based services among family caregivers of patients with end-of-life cancer and provide a framework for developing and executing a tailored telemedicine-based end-of-life care program that addresses the unique needs of family caregivers in mainland China. METHOD: A descriptive phenomenological approach was used. Family caregivers were selected using purposive sampling at a tertiary cancer hospital. One-on-one semi-structured interviews were conducted with the participants from November to December 2022. Colaizz's method was used to analyze the interviews. RESULTS: Fourteen participants participated in interviews. Three themes and ten subthemes were identified: motivation to receive telemedicine services (relief from the burden of home care; access to professional health care services), supportive care needs for telemedicine services (support for symptom management; negative emotional adjustment; death education; daily life care guidance), and functional expectations of telemedicine service platforms (ease of use; real-time online guidance and response; personalized automatic reminder; targeted matching push of health knowledge). CONCLUSION: Family caregivers expressed interest in telemedicine-based services and identified various care needs before receiving telemedicine services. The findings of this study can help policymakers and healthcare providers develop more effective and culturally appropriate telemedicine-based service programs that can better support family caregivers of end-of-life cancer patients.


Asunto(s)
Neoplasias , Telemedicina , Humanos , Cuidadores/psicología , Cuidados Paliativos/métodos , Investigación Cualitativa , Muerte , Neoplasias/terapia , Familia/psicología
2.
J Cell Mol Med ; 27(22): 3465-3477, 2023 11.
Artículo en Inglés | MEDLINE | ID: mdl-37602966

RESUMEN

Periodontal bone regeneration is a major challenge in the treatment of periodontitis. However, the regenerative vitality of periodontal ligament cells (PDLCs) declines in the environment of periodontitis and accompanying oxidative stress. This study aimed to investigate the functional mechanisms of Bach1, a transcriptional suppressor involved in oxidative stress response, and its regulation of PDLC osteogenesis under inflammatory conditions. We observed a significant elevation in Bach1 expression in periodontal tissues with periodontitis and PDLCs under inflammatory conditions. Knockdown of Bach1 alleviated the inflammation-induced oxidative stress level and partly offset the inhibitory effect of inflammatory conditions on osteogenesis, as well as the expression of osteogenic genes BMP6, OPG and RUNX2. Similarly, knockdown of Bach1 protects PDLCs from inflammatory damage to periodontal bone regeneration in vivo. Furthermore, we found that Bach1 could bind to the histone methyltransferase EZH2, and the binding increased under inflammatory conditions. Bach1 enhanced the ability of EZH2 to catalyse H3K27me3 on the promoter region of RUNX2 and BMP6, thus repressing the expression of osteoblastic genes. In conclusion, our study revealed that knockdown of Bach1 effectively rescued the osteogenesis and oxidative stress of PDLCs with inflammation. Bach1 could be a promising target for enhancing periodontal tissue regeneration under periodontitis conditions.


Asunto(s)
Subunidad alfa 1 del Factor de Unión al Sitio Principal , Periodontitis , Humanos , Regeneración Ósea/genética , Diferenciación Celular , Células Cultivadas , Subunidad alfa 1 del Factor de Unión al Sitio Principal/metabolismo , Inflamación/genética , Inflamación/metabolismo , Osteogénesis/genética , Ligamento Periodontal/metabolismo , Periodontitis/genética , Periodontitis/metabolismo
3.
Int Immunopharmacol ; 122: 110414, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37390646

RESUMEN

As a new group of anticancer drugs, immune checkpoint inhibitors (ICIs) have exhibited favorable antitumor efficacy in numerous malignant tumors. Anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4), anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) are three kinds of ICIs widely used in clinical practice. However, ICI therapy (monotherapy or combination therapy) is always accompanied by a unique toxicity profile known as immune-related adverse events (irAEs) affecting multiple organs. The endocrine glands are common targets of irAEs induced by ICIs, which cause type 1 diabetes mellitus (T1DM) when the pancreas is affected. Although the incidence rate of ICI-induced T1DM is rare, it will always lead to an irreversible impairment of ß-cells and be potentially life-threatening. Hence, it is vital for endocrinologists and oncologists to obtain a comprehensive understanding of ICI-induced T1DM and its management. In our present manuscript, we have reviewed the epidemiology, pathology and mechanism, diagnosis, management, and treatments of ICI-induced T1DM.


Asunto(s)
Antineoplásicos Inmunológicos , Antineoplásicos , Diabetes Mellitus Tipo 1 , Neoplasias , Humanos , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Diabetes Mellitus Tipo 1/inducido químicamente , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Antineoplásicos Inmunológicos/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico
4.
J Periodontal Res ; 58(2): 444-455, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36733232

RESUMEN

OBJECTIVE: To investigate the changes in the m6A methylation modification profile of human periodontal ligament cells (hPDLCs) in response to inflammatory conditions. BACKGROUND: Periodontitis is an infectious disease of the periodontal support tissue that leads to the loss of alveolar bone. HPDLCs are primary cells that can repair periodontal tissue defects caused by periodontitis. However, the inflammatory conditions induce inflammatory damage and decrease ossification of hPDLCs. This inflammatory response depends on genetic and epigenetic mechanisms, including m6A methylation. METHODS: HPDLCs were cultured with osteogenic induction medium (NC group), while TNF-α (10 ng/mL) and IL-1ß (5 ng/mL) were added to simulate inflammatory conditions (Inflam group). Then RNA-seq and MeRIP-seq analyses were performed to identify m6A methylation modification in the transcriptome range of hPDLCs. RESULTS: The results showed that the osteogenic differentiation of hPDLCs was inhibited under inflammatory conditions. RNA-seq analysis also revealed that the decreased genes in response to inflammatory conditions were primarily annotated in processes associated with ossification. Compared with the NC group, differentially m6A-methylated genes were primarily enriched in histone modification processes. Among 145 histone modification genes, 25 genes have been reported to be involved in the regulation of osteogenic differentiation, and they include KAT6B, EP300, BMI1, and KDMs (KDM1A, KDM2A, KDM3A, KDM4B, and KDM5A). CONCLUSION: This study demonstrated that the m6A landscape of hPDLCs was changed in response to inflammation. M6A methylation differences among histone modification genes may act on the osteogenic differentiation of hPDLCs.


Asunto(s)
Osteogénesis , Periodontitis , Humanos , Osteogénesis/genética , Células Cultivadas , ARN , Ligamento Periodontal , Epigenoma , Periodontitis/genética , Proteína 2 de Unión a Retinoblastoma/genética , Histona Acetiltransferasas/genética , Histona Demetilasas/genética , Histona Demetilasas con Dominio de Jumonji/genética
5.
J Cell Biochem ; 124(4): 557-572, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36842167

RESUMEN

Gastric cancer (GC) with pulmonary metastasis is one of the deadliest diseases in the world; however, the underlying pathological mechanisms and potential therapeutic targets remain to be elucidated. As exosomes play indispensable roles in the formation of premetastatic niches (PMN) and cancer metastasis. Therefore, investigating the underlying mechanisms of exosome-mediated pulmonary metastasis of GC may shed new light on identifying novel therapeutic targets for GC treatment. GC-derived exosomes were isolated from the conditioned medium of mouse forestomach carcinoma (MFC) cell line. The effects of MFC-derived exosomes on pulmonary macrophage polarization were analyzed by reverse- transcription polymerase chain reaction and flow cytometry. Expression of PD-L1 and other proteins was evaluated by Western blot. Exosomal microRNAs (miRNAs) were analyzed by microarray. GC-derived exosomes (GC-exo) accumulated in high numbers in the lungs and were ingested by macrophages. The extracellular-signal-regulated kinase (ERK) signaling pathway was activated by GC-exo, inducing macrophage immunosuppressive-phenotype differentiation and increased PD-L1 expression. miRNA-sequencing identified 130 enriched miRNAs in GC-exo. Among the enriched miRNAs, miR-92a-3p plays a major role in activating ERK signaling via inhibition of PTEN expression. In addition, inhibiting ERK signaling with PD98059 significantly reduced the expression of PD-L1 in macrophages and, therefore, reversed the immunosuppressive PMN and inhibited the colonization of GC cells in the lungs. This study identified a novel mechanism of GC-exo mediated PD-L1 expression in lung macrophages that facilitates lung PMN formation and GC pulmonary metastasis, which also provided a potential therapeutic target for GC with pulmonary metastasis treatment.


Asunto(s)
Exosomas , Neoplasias Pulmonares , MicroARNs , Neoplasias Gástricas , Animales , Ratones , Neoplasias Gástricas/patología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Antígeno B7-H1/genética , Antígeno B7-H1/metabolismo , Exosomas/metabolismo , Línea Celular Tumoral , MicroARNs/genética , MicroARNs/metabolismo , Macrófagos/metabolismo , Neoplasias Pulmonares/metabolismo
6.
J Cancer Res Clin Oncol ; 149(7): 3301-3312, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35925427

RESUMEN

PURPOSE: Omics data are crucial for medical diagnosis as it contains intrinsic biomedical information. Multi-omics integrated analysis has become a new direction for scientists to explore life mechanisms. Nevertheless, the quality of complex omics data often varies greatly due to different samples or even different omics types, it is challenging to dynamically capture the uncertainty for different kinds of omics data. METHODS: This paper proposes a uncertainty-aware dynamic integration framework for multi-omics classification. The framework consists of three modules: deep embedding, confidence prediction, and downstream tasks. The deep embedding module extract key information from multi-omics data to obtain a low-dimensional feature representation which is used to train downstream tasks. Combined with the deep embedding module, the confidence prediction module is used to dynamically capture the uncertainty of the data. We introduce "confidNet" to assign a confidence value for each type of omics data, which is used for dynamic integration between multi-omics. RESULTS: Compared with other integration methods, the proposed method can contain more crucial biomedical information in the obtained low-dimensional representation. Our framework realizes reliable integration among multiple omics, and it can still achieve high accuracy on small sample data sets. We have verified the effectiveness of the model in a large number of experiments. CONCLUSION: Our framework can be widely applied to high-dimensional omics data and has great potential to facilitate medical decision-making and biological analysis.


Asunto(s)
Multiómica , Neoplasias , Humanos , Incertidumbre , Neoplasias/diagnóstico , Neoplasias/genética
7.
J Mater Chem B ; 10(30): 5774-5783, 2022 08 04.
Artículo en Inglés | MEDLINE | ID: mdl-35856878

RESUMEN

Matrix metalloproteinases (MMPs) are important biomarkers for a number of diseases. Thus, the precise determination of MMP activity is of crucial importance. Herein, we report a ratiometric fluorescence method for the sensitive and selective sensing of MMP activity. A number of positively charged MMP substrates (polypeptides) were designed and prepared. These polypeptides could induce aggregation of a negatively charged perylene diimide derivative (PC1). As a result, excimer fluorescence of PC1 was observed. Addition of the corresponding MMP resulted in cleavage of the polypeptide chain and dis-aggregation of PC1, which led to turning on of the PC1 monomer fluorescence. Based on the ratio of the monomer (545 nm, IM) and the excimer (680 nm, IM) fluorescence intensity changes, a ratiometric method I545/I680) was established to detect MMP activity. The enzymatic activity of a number of MMPs (MMP-1, 2, 3, 7, 9 and 13) could be determined with a limit of detection of 4.8, 2.2, 16, 6.0, 1.7 and 5.5 ng mL-1, respectively. Using MMP-2 and MMP-9 as examples, flavonoid herbal extracts as potential inhibitors were studied. It was observed that mangiferin, apigenin, quercetin and isoliquiritigenin had significant inhibiting effects on the enzyme activity. And these herbal extracts also inhibited tumor cell metastasis. Moreover, the developed strategy was also employed to determine the concentration of MMP-9 in human saliva samples. Since the method relies on only noncovalent interactions between the polypeptide and PC1, no covalent labeling of fluorescence dye on the polypeptide substrate is required, and the method is thus simple, broad-spectrum inexpensive and effective. It has the potential to be developed into a clinical test kit.


Asunto(s)
Perileno , Colorantes Fluorescentes , Humanos , Metaloproteinasa 9 de la Matriz , Metaloproteinasas de la Matriz , Péptidos
8.
Contrast Media Mol Imaging ; 2022: 5787981, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35601568

RESUMEN

Functional analysis of immune subtypes in hepatocellular carcinoma has attracted much attention due to its advantages in solving some optimization problems. At present, the research on the immune subtype of hepatocellular carcinoma is still in its infancy, and the high stability of its system still has problems. Based on fuzzy logic and evolutionary algorithms, this paper constructs a Mate analysis of the optimization problem of immune subtypes and dynamic optimization problems of hepatocellular carcinoma. The model conducts in-depth analysis and research on the biological immune subtype system, solving the problems of reliable information processing and body defense. Tested with existing test functions, very competitive results were achieved. The simulation results show that the improved algorithm based on data statistics has global search ability, the solution accuracy reaches 0.931, and the stability reaches 88.1%.


Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Algoritmos , Simulación por Computador , Lógica Difusa , Humanos
9.
J Med Chem ; 65(5): 3923-3942, 2022 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-35230841

RESUMEN

Regulating SOS1 functions may result in targeted pan-KRAS therapies. Small-molecule SOS1 inhibitors showed promising anticancer potential, and the most advanced inhibitor BI 1701963 is currently under phase I clinical studies. SOS1 agonists provide new opportunities to treat cancer; however, the underlying mechanisms still warrant investigation. We here report the discovery of the first SOS1 PROTACs designed uniquely by connecting a VHL ligand to the reported SOS1 agonist, ensuring that the observed inhibitory activity results from degraders. The best compound 9d induced SOS1 degradation in various KRAS-driven cancer cells and displayed superior antiproliferation activity compared to the agonist itself. Tumor xenograft study clearly showed the promising antitumor potency of 9d against human lung cancer. This study provides good evidence of using agonists to design SOS1 PROTACs and demonstrates that targeted SOS1 degradation represents an effective therapeutic strategy for overcoming KRAS-driven cancers.


Asunto(s)
Antineoplásicos , Neoplasias Pulmonares , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Humanos , Péptidos y Proteínas de Señalización Intercelular , Neoplasias Pulmonares/tratamiento farmacológico , Mutación , Proteínas Proto-Oncogénicas p21(ras)/genética
10.
Bioorg Med Chem Lett ; 64: 128680, 2022 05 15.
Artículo en Inglés | MEDLINE | ID: mdl-35306167

RESUMEN

Aberrantly activated Janus kinase 3 (JAK3) has been constantly detected in various immune disorders and hematopoietic cancers, suggesting its potential of being an attractive therapeutic target for these indications. Clinical benefits of drugs selectively targeting JAK3 versus pan-JAK inhibitors remain unclear. In this study, we report the design and synthesis of a new series of JAK3 covalent inhibitors with a pyrido[2,3-d]pyrimidin-7-one scaffold. After the extensive SAR study, compound 10f emerged to be the most potent JAK3 inhibitor with an IC50 value of 2.0 nM. It showed excellent selectively proliferation inhibitory activity against U937 cells harboring JAK3 M511I mutation, while remained weakly active to the other tested cancer cells. Compound 10f also dose-dependently inhibited the phosphorylation of JAK3 and its downstream signal STAT5 in U937 cells. Taken together, 10f may serve as a promising tool molecule for treating cancers with aberrantly activated JAK3.


Asunto(s)
Janus Quinasa 3 , Inhibidores de Proteínas Quinasas , Janus Quinasa 1 , Janus Quinasa 2 , Janus Quinasa 3/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA